Clinical Trial Update: Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a multigene risk score plus Ki-67 dynamic assessment to guide neoadjuvant endocrine therapy with or without CDK4/6 inhi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors

Snippet

Sponsor: Peking University | Conditions: Breast Cancer, Early-stage Breast Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION